How should women with pre-eclampsia be followed up? New insights from mechanistic studies

Alexandre Hertig, Suzanne Watnick, Helena Strevens, Henri Boulanger, Nadia Berkane, Eric Rondeau

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Understanding of the maternal syndrome of pre-eclampsia has greatly improved over the past 5 years. Specifically, the notion has emerged that the placenta is a source of antiangiogenic factors, such as soluble fms-like tyrosine kinase 1, that can progressively impair the mother's vascular and glomerular function throughout pregnancy. This impairment can be harmless during normal pregnancy, but in cases of defective placentation, concentrations of antiangiogenic factors increase to a level that compromises vital vascular functions in the short term and jeopardizes long-term maternal and fetal outcomes. In both pre-eclamptic and healthy pregnancies, the transient imbalance between angiogenic and antiangiogenic factors elicited by pregnancy acts as a 'stress test' for the endothelium, particularly in the glomerular capillary bed. Women who do not pass this test (i.e. those who develop pre-eclampsia or gestational hypertension) should be screened for glomerular disease, and their cardiovascular risk should be carefully monitored throughout life.

Original languageEnglish (US)
Pages (from-to)503-509
Number of pages7
JournalNature Clinical Practice Nephrology
Volume4
Issue number9
DOIs
StatePublished - Sep 2008

Fingerprint

Pre-Eclampsia
Pregnancy
Mothers
Blood Vessels
Prehypertension
Vascular Endothelial Growth Factor Receptor-1
Placentation
Pregnancy Induced Hypertension
Angiogenesis Inducing Agents
Exercise Test
Placenta
Endothelium
Cardiovascular Diseases

Keywords

  • Gestational hypertension
  • Glomerular endotheliosis
  • Pre-eclampsia
  • Pregnancy
  • sFlt-1

ASJC Scopus subject areas

  • Nephrology

Cite this

Hertig, A., Watnick, S., Strevens, H., Boulanger, H., Berkane, N., & Rondeau, E. (2008). How should women with pre-eclampsia be followed up? New insights from mechanistic studies. Nature Clinical Practice Nephrology, 4(9), 503-509. https://doi.org/10.1038/ncpneph0880

How should women with pre-eclampsia be followed up? New insights from mechanistic studies. / Hertig, Alexandre; Watnick, Suzanne; Strevens, Helena; Boulanger, Henri; Berkane, Nadia; Rondeau, Eric.

In: Nature Clinical Practice Nephrology, Vol. 4, No. 9, 09.2008, p. 503-509.

Research output: Contribution to journalArticle

Hertig, A, Watnick, S, Strevens, H, Boulanger, H, Berkane, N & Rondeau, E 2008, 'How should women with pre-eclampsia be followed up? New insights from mechanistic studies', Nature Clinical Practice Nephrology, vol. 4, no. 9, pp. 503-509. https://doi.org/10.1038/ncpneph0880
Hertig, Alexandre ; Watnick, Suzanne ; Strevens, Helena ; Boulanger, Henri ; Berkane, Nadia ; Rondeau, Eric. / How should women with pre-eclampsia be followed up? New insights from mechanistic studies. In: Nature Clinical Practice Nephrology. 2008 ; Vol. 4, No. 9. pp. 503-509.
@article{e5efea4dcb9c48acbf56509e6abbbc50,
title = "How should women with pre-eclampsia be followed up? New insights from mechanistic studies",
abstract = "Understanding of the maternal syndrome of pre-eclampsia has greatly improved over the past 5 years. Specifically, the notion has emerged that the placenta is a source of antiangiogenic factors, such as soluble fms-like tyrosine kinase 1, that can progressively impair the mother's vascular and glomerular function throughout pregnancy. This impairment can be harmless during normal pregnancy, but in cases of defective placentation, concentrations of antiangiogenic factors increase to a level that compromises vital vascular functions in the short term and jeopardizes long-term maternal and fetal outcomes. In both pre-eclamptic and healthy pregnancies, the transient imbalance between angiogenic and antiangiogenic factors elicited by pregnancy acts as a 'stress test' for the endothelium, particularly in the glomerular capillary bed. Women who do not pass this test (i.e. those who develop pre-eclampsia or gestational hypertension) should be screened for glomerular disease, and their cardiovascular risk should be carefully monitored throughout life.",
keywords = "Gestational hypertension, Glomerular endotheliosis, Pre-eclampsia, Pregnancy, sFlt-1",
author = "Alexandre Hertig and Suzanne Watnick and Helena Strevens and Henri Boulanger and Nadia Berkane and Eric Rondeau",
year = "2008",
month = "9",
doi = "10.1038/ncpneph0880",
language = "English (US)",
volume = "4",
pages = "503--509",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - How should women with pre-eclampsia be followed up? New insights from mechanistic studies

AU - Hertig, Alexandre

AU - Watnick, Suzanne

AU - Strevens, Helena

AU - Boulanger, Henri

AU - Berkane, Nadia

AU - Rondeau, Eric

PY - 2008/9

Y1 - 2008/9

N2 - Understanding of the maternal syndrome of pre-eclampsia has greatly improved over the past 5 years. Specifically, the notion has emerged that the placenta is a source of antiangiogenic factors, such as soluble fms-like tyrosine kinase 1, that can progressively impair the mother's vascular and glomerular function throughout pregnancy. This impairment can be harmless during normal pregnancy, but in cases of defective placentation, concentrations of antiangiogenic factors increase to a level that compromises vital vascular functions in the short term and jeopardizes long-term maternal and fetal outcomes. In both pre-eclamptic and healthy pregnancies, the transient imbalance between angiogenic and antiangiogenic factors elicited by pregnancy acts as a 'stress test' for the endothelium, particularly in the glomerular capillary bed. Women who do not pass this test (i.e. those who develop pre-eclampsia or gestational hypertension) should be screened for glomerular disease, and their cardiovascular risk should be carefully monitored throughout life.

AB - Understanding of the maternal syndrome of pre-eclampsia has greatly improved over the past 5 years. Specifically, the notion has emerged that the placenta is a source of antiangiogenic factors, such as soluble fms-like tyrosine kinase 1, that can progressively impair the mother's vascular and glomerular function throughout pregnancy. This impairment can be harmless during normal pregnancy, but in cases of defective placentation, concentrations of antiangiogenic factors increase to a level that compromises vital vascular functions in the short term and jeopardizes long-term maternal and fetal outcomes. In both pre-eclamptic and healthy pregnancies, the transient imbalance between angiogenic and antiangiogenic factors elicited by pregnancy acts as a 'stress test' for the endothelium, particularly in the glomerular capillary bed. Women who do not pass this test (i.e. those who develop pre-eclampsia or gestational hypertension) should be screened for glomerular disease, and their cardiovascular risk should be carefully monitored throughout life.

KW - Gestational hypertension

KW - Glomerular endotheliosis

KW - Pre-eclampsia

KW - Pregnancy

KW - sFlt-1

UR - http://www.scopus.com/inward/record.url?scp=50249147366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249147366&partnerID=8YFLogxK

U2 - 10.1038/ncpneph0880

DO - 10.1038/ncpneph0880

M3 - Article

VL - 4

SP - 503

EP - 509

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 9

ER -